• CONCLUSION: The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.
INTRODUCTION
T reatment options for retinal eye diseases have expanded over the years, and the increasing number of clinical studies on the effectiveness of these treatments has raised attention to the management regime of these eye diseases. Ranibizumab (Lucentis) is a recombinant humanized monoclonal antibody fragment that binds to vascular endothelial growth factor A (VEGFA) and prevents it from binding to receptors, thus suppressing neovascularization [1] . Ranibizumab is currently one of the most common drugs used for treating age-related macular degeneration (AMD) [2] , macular edema following retinal vein occlusion [3] , diabetic macular edema (DME) [3] and diabetic retinopathy [4] . Photodynamic therapy (PDT) has also been used to treat abnormal growth of blood vessels in exudative AMD [5] , pathologic myopia [6] and histoplasmosis [7] . Ranibizumab and PDT have been the 'gold standard' treatment options for AMD and polypoidal choroidal vasculopathy (PCV) in many countries, but treatment options are now more varied [1, 8] . While many treatment pattern studies have been reported in other countries [9] [10] [11] [12] , the majority of these have been on patients of European descent with fewer studies investigating the treatment trends in Asian populations [8, [13] [14] . It is recognized that the trends in Asia might be different due to heterogeneity [15] [16] [17] since the Asian region stretches from far north-eastern Asian nations, such as Japan and Korea, through to Southeast Asian countries, such as Malaysia and Singapore, and across to India. Additionally, this heterogeneity might result in different prevalences of retinal diseases resulting in different treatment trends; for example, the prevalence of PCV in the Asian population is much higher than in the European population [13, 16, 18] . Such conflicting results have been reported on treatments in Asia, and generally there is a lack of information available on the treatment patterns of ranibizumab and PDT, especially in Malaysia. This prompted us to conduct this retrospective study to determine how treatment patterns of ranibizumab and PDT changed between 2010 and 2014.
SUBJECTS AND METHODS
This study is a 5-year retrospective cohort study of patients who had attended the Ophthalmology Clinic at Hospital Selayang between January 2010 and December 2014. Hospital Selayang is the most referred hospital for eye diseases in Malaysia. Approval for this study was obtained from the Medical Research Ethics Committee (MREC) of the National Medical Research Register (NMRR) (Ethics No.NMRR-14-1176-21475). The cohort was selected from the medical records stored in Hospital Selayang's Electronic Medical Record (EMR) database. Inclusion criteria for the study were patients with eye diseases who received intravitreal ranibizumab injections and PDT at the Ophthalmology Clinic, Hospital Selayang between 2010 and 2014. Malaysian citizens were recruited who belonged to one of the nation's three main ethnic groups: Malays, Chinese and Indians. Patients who did not receive ranibizumab injections and PDT, non-Malaysians and those whose medical records were non-retrievable or incomplete were excluded from this study. All data were retrieved from the patient's medical records, and was based on their first visit to the eye clinic in the respective year. Socio-demographic data relating to age, gender and ethnicity was obtained. In addition, data on any clinical history of co-morbidities, diagnostic procedures performed for each patient [including optical coherence tomography (OCT) and fundus angiography (FFA) or indocyanine green (ICG)] was also taken. The diagnoses of eye disease during the patient's visit to the clinic were recorded, and treatment options given to the patients were classified into ranibizumab monotherapy, ranibizumab combined with PDT and PDT monotherapy. All statistical analyses were undertaken using the Statistical Package for Social Sciences (SPSS version 22, Chicago, IL, USA). Findings were described by frequencies, percentages, means and standard deviations (SD). A Chi-square test was used to calculate the association between socio-demographic, co-morbidities, diagnostic procedures and treatments. Analysis of variance (ANOVA) was used to analyse associations of continuous variables. Multiple logistic regressions were used to determine the parameters associated with each treatment. Data with zero value in any treatment groups was excluded from logistic regression analyses. All cases were analysed with 95% confidence intervals (CI), and the level of significance was set at P < 0.05.
RESULTS
The broad database search of medical records from January 2010 to December 2014 retrieved a total of 4240 patients. After excluding duplicates and irrelevant records (due to patients not receiving ranibizumab or PDT therapy in the clinic, non-Malaysians and non-retrievable or incomplete medical records), a final total of 821 patients were included in this study. Details on patient selection are presented in Figure 1 . Table 1 shows the demographic and co-morbidity information of all retained subjects. Overall, the mean age was 65.9± 11.73y; 63.1% of participants were male, and 74.4% were aged ≥60y. Although no significant difference was observed between the years, from the mean age of patients it can be observed that in 2014 the patients receiving treatment in the clinic were younger (64.7±11.34y) than in 2010 (68.8±10.35y). No significant difference was observed between the genders, Email:ijopress@163.com mellitus (37.2%), followed by ranibizumab combined with PDT (21.8%) and PDT (17.1%). Significant differences were also observed in the diagnostic procedures and diagnoses of patients based on different treatments prescribed to the patients. Patients prescribed with ranibizumab monotherapy had a higher frequency of undergoing OCT (P<0.001) and OCT+FFA (P<0.001) diagnostic procedures compared to the other treatment groups. Those prescribed with ranibizumab combined with PDT mostly underwent the OCT+ICG procedure (P<0.001), while PDT was higher in the OCT+FFA+ICG procedure (P=0.004). Furthermore, those receiving ranibizumab monotherapy were significantly higher among AMD patients (30.8%), DME (16.1%), ADED (8.7%), central retinal vein occlusion (CRVO) (4.8%), branch retinal vein occlusion (BRVO) (4.1%), and cystoid macular edema (CME) (2.7%). PCV patients were significantly the most prescribed with ranibizumab combined with PDT (84.4%) compared to ranibizumab monotherapy (30.6%) and PDT (58.2%) (P<0.001). Meanwhile, patients with central serous chorioretinopathy (CSCR) and choroidal hemangioma were significantly prescribed with PDT monotherapy, at frequencies of 19.0% and 7.6% respectively. Multiple logistic regression models were performed to examine the socio-demographic factors, co-morbidities, diagnostic procedures and patient diagnoses associated with each of the treatment groups (Table 3) . Among patients prescribed ranibizumab monotherapy, significant differences were observed in age and ethnicity compared to those who were not prescribed ranibizumab monotherapy. Those patients receiving ranibizumab monotherapy were at increased risk at an older age (OR=1.01, 95%CI=1.00- [19] [20] [21] [22] have been conducted to study the effects of the treatment, and the use of ranibizumab in treating patients with AMD and other retinal diseases has increased over the years [13, 23] . PDT was also reportedly effective in reducing the risk of moderate to severe vison loss, such as in subfoveal CNV due to AMD [24] [25] [26] and also in PCV [20, 27] . Since these findings, researchers have studied the effects of both treatments combined and their effects in monotherapy [28] [29] . The present study has shown that the number of ranibizumab and PDT prescriptions increased over the years, suggesting an increase in the number of patients with retinal diseases that require medical treatments. Both treatments displayed significantly different trends, and the use of ranibizumab increased over the years while PDT prescriptions fell. In 2010 PDT was frequently prescribed, while in 2014 ranibizumab was the most-frequently prescribed treatment. This could be because ranibizumab was only approved by the Food and Drug Administration (FDA) in 2006 [30] and was phased in gradually by ophthalmologists. Since then, research has expanded from studying the efficacy and safety of anti-VEGF to investigating which anti-VEGF treatment is most efficient at improving the visual outcomes of affected patients [21] [22] 27, 31] , proving that ranibizumab has been used at an increasing rate including within the present study. The increasing trend of ranibizumab use can also be seen in the Singapore National Eye Centre from 2009 to 2012 [13] and also in the United States between 2005 and 2014 [10] .
Patterns of ranibizumab and PDT treatment
Unlike ranibizumab, the use of PDT monotherapy was seen to decrease in the present study. However, the combination therapy of ranibizumab and PDT displayed a similar trend over the years. Before the introduction of ranibizumab, PDT was introduced in the 1990s and was used in the treatment of CNV secondary to AMD and delaying legal blindness of patients [32] . PDT was then introduced as an effective and safe treatment for subfoveal or juxtafoveal AMD and PCV, due to the minimal damage the treatment does to the retina [25] [26] [27] . However, it was observed that polypoidal lesions are highly recurrent over long periods [33] , and PDT was associated with the risk of submacular hemorrhages in PCV [34] . Anti-VEGF was then introduced into the treatment of PCV [27] , but was not as efficient as treating CNV in AMD [31] . The results from an ICG procedure showed a reduction in leakage but no regression in the choroidal vascular changes in PCV [35] . A revolution in combining ranibizumab and PDT treatments was thus introduced, and had positive results in reducing leakages together with inducing regression in polyps [27] . This includes the present study, as higher numbers of PCV patients were prescribed with the combination therapy (84.4%) compared to PDT (58.2%) and ranibizumab monotherapy (30.6%). Similar trends can be observed in the United States, where PDT monotherapy decreased from 12.8% in 2006 to 5.3% in 2008 [9] . Apart from the trends in ranibizumab and PDT treatments, the present study also noted the different parameters associated with the prescribed treatments. Patients receiving treatments had a mean age of over 60, while the group receiving ranibizumab combined with PDT were older compared to the other two monotherapy groups. Since high levels of AMD and PCV were recorded in patients prescribed with ranibizumab and PDT, the age groups were marked high due to the fact that age is the most common risk factor for both AMD and PCV. This may merely be because of the long latent period of the disease [36] . Older patients with AMD and PCV were also reported by Krishnaiah et al [37] and Cheung et al [38] . There were significant differences among the different ethnicities. Chinese patients were the most frequent group to receive treatments in the clinic, suggesting that Chinese people have a higher incidence of retinal disease. This trend is similar to that reported by the the 4 th National Eye Database in Malaysia, which found that among AMD patients in 2008 ethnically Chinese (52.1%) patients had the highest incidence, followed by Malays (33.1%) and Indians (13.6%) [39] . When compared via regression analysis, Chinese people were reported to most likely to receive combination therapy and also PDT monotherapy. This could be related to the high number of PCV patients in both of these two treatment groups. Since Malaysia has a multi-ethnic population, we compared our findings with a study from a centre in Singapore. This reported that Chinese patients were alsoat a higher frequency, with 57.5%, followed by Malays (28.5%) and Indians (14.0%) among their PCV patients [40] . Another study in Singapore again with higher frequency of Chinese patients (88.2%) and 7.8% of Malays, compared to 1% of Indians [38] . Our observations that PCV may be frequent in Chinese is also supported by Wen et al [41] who reported 22.3% of 166 patients in their study were Chinese and diagnosed with PCV. Co-morbidities of patients with hypertension and diabetes mellitus were reported to be significant in three treatment groups in the present study. Similarly, these findings are related to the risk factors of the eye diseases that require a particular treatment, in this case AMD and PCV. Hypertension and diabetes mellitus were reported to be risk factors in AMD and PCV [38, 42] , but not all studies reported the same associations [43] [44] . Additionally, the diagnostic procedures conducted in the clinic were consistent with procedures to detect retinal diseases. OCT was also reported to be a good diagnostic tool in detecting classic CNV for newly-diagnosed patients. However, in differentiating classic CNV from occult CNV, FFA is considered to be an accurate diagnostic procedure [45] [46] . This is reflected in the regression analysis findings from the present study, as OCT and FFA procedures were highest among AMD patients receiving ranibizumab monotherapy. Meanwhile, ICG procedures were frequent among those receiving the combination therapy and PDT, which is a treatment most frequently prescribed for PCV patients. ICG was shown to be more sensitive at detecting polypoidal dilation in the choroidal vascular network of PCV when compared to FFA, which may appear as occult CNV [47] [48] . Furthermore, findings from the present study are consistent with the types of treatments most commonly prescribed amongst AMD and PCV patients. In the clinic studied, AMD patients were being prescribed with ranibizumab monotherapy, as anti-VEGF agents give better results when treating such individuals. Rosenfeld et al [1] reported that intravitreal administration of ranibizumab prevents vision loss and improves visual acuity in AMD patients. Similarly, in Japan, Matsumiya et al [31] reported ranibizumab resulted in better visual outcomes among AMD patients compared to PCV patients. PDT monotherapy and ranibizumab combined with PDT was more commonly prescribed to PCV patients in the present study, as PDT is considered more efficacious at treating PCV patients compared to AMD, similar to the findings several studies [49] [50] [51] . Tomita et al [52] reported that when PDT is combined with ranibizumab therapy, the polypoidal lesions among PCV patients disappeared completely in 79.1% of cases, with a substantial reduction in exudative change [52] . Wong et al [53] reported that when PDT was combined with ranibizumab, polyp regression or disease activity resolution was observed for at least nine months after treatment, but only in PCV patients who had a single small polyp. This supports the reason ranibizumab combined with PDT was frequently prescribed to PCV patients in this study.
In the present study, administration of ranibizumab and PDT was also prescribed to patients with other retinal diseases. The use of ranibizumab and PDT is recognized in the management of AMD and PCV. Meanwhile, the efficacy and safety of ranibizumab conducted by many clinical studies which observed the improvement in best corrected visual acuity (BCVA) of patients, meant it was also suggested for macular edema patients following retinal vein occlusions [54] [55] [56] and diabetic eye diseases [3, 57] . CSCR and choroidal hemangioma patients were also observed to receive the ranibizumab treatment. However, they are more commonly prescribed with the PDT monotherapy. Erikitola et al [58] observed changes in the BCVA, OCT and FFA of CSCR patients treated with PDT, and suggested it was a useful treatment. This supports a study on choroidal hemangioma that reported an improvement in BCVA and the elimination of subretinal fluid in choroidal hemangioma patients treated with PDT monotherapy [59] . All these findings are in accordance with the use of ranibizumab and PDT in the present study.
In conclusion, we reported the patterns of ranibizumab and PDT treatment in a Malaysian population at a tertiary care setting. To our knowledge, this is the first comprehensive report on patterns of ranibizumab and PDT treatment from Malaysia. However, the present study has to be interpreted within the context of its limitations. Our study focused only on the prevalence of patterns of treatment in a single tertiary centre without following up patients in their response to the given treatment. The study's retrospective nature and small sample size are also limitations. Moreover, the findings reported in this paper were recorded between 2010 and 2014. The prevalence of retinal diseases is expected to increase in future. The data thus needs to be updated further on the patterns of treatment, and the prevalence is needed in order to establish our findings for public health education and the prevention of retinal diseases.
